Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-021-02006-7
Abstract: Until recently, no effective targeted therapies for FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML) were available in Japan. The FLT3 inhibitor, gilteritinib, was approved in Japan for patients with FLT3mut+ R/R AML based on… read more here.
Keywords: relapsed refractory; gilteritinib; refractory acute; myeloid leukemia ... See more keywords
4-Hydroxyphenyl Retinamide Preferentially Targets FLT3 Mutated Acute Myeloid Leukemia via ROS Induction and NF-κB Inhibition
Sign Up to like & getrecommendations! Published in 2020 at "Current Medical Science"
DOI: 10.1007/s11596-020-2259-0
Abstract: FMS-like tyrosine kinase 3 (FLT3) mutation is strongly associated with poor prognosis in acute myeloid leukemia (AML). Though many FLT3 inhibitors have been developed for clinical application with 34%–56% complete remission rate, patients would develop… read more here.
Keywords: hydroxyphenyl retinamide; myeloid leukemia; flt3 mutated; aml cells ... See more keywords
Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2054801
Abstract: ABSTRACT Introduction FLT3 inhibitors have been recently introduced as novel treatment targets in patients with FLT3-mutated acute myeloid leukemia (AML). Midostaurin is an oral multikinase inhibitor that targets multiple receptor tyrosine kinases including FLT3 and… read more here.
Keywords: mutated acute; flt3 mutated; acute myeloid; midostaurin ... See more keywords
Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2023.2202849
Abstract: ABSTRACT Introduction Approximately one-third of patients with acute myelogenous leukemia (AML) harbor mutations in the fms-like tyrosine kinase 3 (FLT3) gene. The features regarding prognostic impact of FLT3 mutated AML have been widely investigated and… read more here.
Keywords: flt3; myelogenous leukemia; mutated aml; acute myelogenous ... See more keywords
Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan
Sign Up to like & getrecommendations! Published in 2022 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyac069
Abstract: Abstract Objective Gilteritinib received approval for the treatment of FLT3-mutated relapsed or refractory acute myeloid leukemia in Japan in 2018. In accordance with regulatory requirements, we conducted a multicenter, observational surveillance of gilteritinib use in… read more here.
Keywords: surveillance; flt3 mutated; mutated relapsed; relapsed refractory ... See more keywords
Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006489
Abstract: Key Points Patients with FLT3-mutated R/R AML benefitted from gilteritinib regardless of comutations, FLT3-ITD allelic ratio, or FLT3-ITD length. Resistance to gilteritinib was associated with acquired Ras/MAPK pathway gene mutations and FLT3 F691L mutations. read more here.
Keywords: flt3; molecular profile; flt3 mutated; mutated relapsed ... See more keywords
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.00602
Abstract: PURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) but seldom reduces FLT3mut burden or induces sustained efficacy. Gilteritinib combines synergistically with the BCL-2… read more here.
Keywords: flt3; relapsed refractory; flt3 mutated; flt3 inhibitor ... See more keywords
Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.16304
Abstract: Activation of the Hedgehog pathway has been implicated in the pathogenesis of several tumor types including myeloid leukemia. Previously we demonstrated that overexpression of Hedgehog downstream mediators GLI1/2 confers an adverse prognosis to patients with… read more here.
Keywords: myeloid leukemia; inhibition; flt3 mutated; flt3 ... See more keywords
AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial.
Sign Up to like & getrecommendations! Published in 2021 at "Future oncology"
DOI: 10.2217/fon-2021-0388
Abstract: AMELIORATE is a Phase III, randomized trial aiming to personalize treatment intensity in FLT3-mutated acute myeloid leukemia. The current study provides an early appraisal of chemosensitivity based on peripheral blasts clearance, as assessed by multiparameter flow cytometry, from… read more here.
Keywords: myeloid leukemia; flt3 mutated; based peripheral; acute myeloid ... See more keywords
Targeting TKI-Activated NFKB2-MIF/CXCLs-CXCR2 Signaling Pathways in FLT3 Mutated Acute Myeloid Leukemia Reduced Blast Viability
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10051038
Abstract: Disease relapse is a common cause of treatment failure in FMS-like tyrosine kinase 3 (FLT3) mutated acute myeloid leukemia (AML). In this study, to identify therapeutic targets responsible for the survival and proliferation of leukemic… read more here.
Keywords: mutated acute; myeloid leukemia; flt3 mutated; acute myeloid ... See more keywords
Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms22158092
Abstract: The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in one-third of patients with de novo acute myeloid leukemia (AML). Mutated FLT3 variants are constitutively active kinases signaling via AKT kinase, MAP kinases, and STAT5.… read more here.
Keywords: inhibitor; mcl1 inhibitor; treatment; flt3 mutated ... See more keywords